Eyeonix faces substantial going-concern doubt because liquidity cannot fund at least the next 12 months. Nine-month revenue was $83,700 and net loss $28,029, compared with $44,600 and $72,900; controls were ineffective at September 30, 2026.
Net loss$16.68KDiluted EPS$0.00
Read from the MD&A section5 source passages
Eyeonix was incorporated to develop, build, operate and franchise casual eating establishments.At September 30, 2026, we had $70,958 in total assets, all current, $36,322 in current liabilities and a $2,075,227 accumulated deficit. Our current liquidity resources are not sufficient to fund the anticipated level of operations for at least the next 12 months from the date these consolidated financial statements were issued.We recognized $83,700 and $44,600 in revenues during the nine months ended September 30, 2026 and 2025, respectively, from providing digital marketing services.As a result of the above, we recognized net losses of $28,029 and $72,900 for the nine months ended September 30, 2026 and 2025, respectively.Based on that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2026 due to the material weakness in our internal controls over financial reporting, including our failure to design and maintain formal accounting policies, processes, and controls to analyze, and account for complex transactions as well as a need for additional accounting personnel who have the requisite experience in SEC reporting regulation.Open the document at this passage
Eyeonix AIQ proposed to acquire COMMAND HEALGRID source code from Eyeonix Greece through its wholly owned subsidiary Eyeonix MedAIQ, issuing 30,600,000 common shares as consideration and assuming ongoing development; the transaction is expected to finalize this calendar year.
Other events3 source passages
On October 30, 2026, Eyeonix MedAIQ, Inc., a Wyoming corporation and wholly owned subsidiary of Eyeonix AIQ, Inc. (the “Company”), entered into a Memorandum of Understanding (the “MOU”) with Eyeonix S.A., a company organized under the laws of Greece (“Eyeonix Greece”), regarding the proposed acquisition of the source code for the software known as COMMAND HEALGRID (the “Asset”), which was developed by Eyeonix Greece.Under the proposed transaction, Eyeonix Greece would transfer to Eyeonix MedAIQ all of its rights in the Asset, and Eyeonix MedAIQ would assume responsibility for the Asset’s ongoing development. As consideration, the Company would issue to Eyeonix Greece 30,600,000 shares of its common stock.The transaction is expected to finalize in this calendar year.Open the document at this passage
Eyeonix AIQ, Inc. added Dr. Rohit Chitale and Dr. Grigoris Gerotziafas to its board of directors, effective immediately, at an Extraordinary Meeting of the Board of Directors.
